October 23-25, 2024, at
the U.S. Pharmacopeia Campus, Rockville, MD
HOUSTON, Aug. 14,
2024 /PRNewswire/ -- The Standardizing Laboratory
Practices in Pharmacogenomics (STRIPE) Collaborative Community, an
initiative of the American Society of Pharmacovigilance (ASP) with
FDA participation, is set to host its Annual Meeting and Consensus
Workshop from October 23-25, 2024, at
the U.S. Pharmacopeia Campus in Rockville, MD. This workshop represents an
important milestone in the ongoing effort to develop and harmonize
standards for pharmacogenomic in vitro diagnostic and lab-developed
testing, seeking to align stakeholder perspectives and accelerate
the adoption of personalized medicine practices as standard of
care.
About STRIPE: STRIPE is a continuing forum where
public and private sector members collaborate to integrate
personalized medicine into standard healthcare practices. Convened
by the American Society of Pharmacovigilance, STRIPE unites
patients, providers, industry leaders, regulators, payers, and
other key stakeholders to address complex challenges and achieve
common objectives in the field of pharmacogenomics.
Workshop Dates: October 23-25, 2024
Location: US Pharmacopeia (USP) Campus, 12601
Twinbrook Pkwy, Rockville, MD
Purpose: Develop consensus statements related to
pharmacogenomic testing and practice
Registration: Available online at
www.stopadr.org/events
The workshop will address stakeholder challenges in
pharmacogenomics, including policy and implementation
considerations. It will also evaluate evidence review processes
from clinical, economic, and regulatory perspectives, and seek to
ensure equity in access to pharmacogenomic testing. The event
features workshops on clinical decision support, clinical and
laboratory challenges, health equity, education, and study design
considerations, culminating in voting on workshop results to inform
consensus-driven standards. The outcomes of this workshop could
significantly impact the future of personalized medicine such that
pharmacogenomic testing becomes an integral part of healthcare.
Targeted Audience: Persons/organizations who would be
impacted by pharmacogenomic testing standards including Industry,
academia, healthcare, patient advocates, regulators, payers, and
more, from strong adopters to clinical skeptics. Members of the
press: please contact us for more information regarding the press
conference.
Event Highlights:
- Four panel discussions offering insights from various
stakeholder perspectives
- Six consensus workshops for in-depth discussions based
on attendee preferences
- Anonymized voting to gather trends in perspectives
across health sectors
- Pre-meeting briefing packet and survey to inform
workshop discussions
Join Us: Be a part of this pivotal event to
collaborate, innovate, and lead the way in pharmacogenomics. Your
participation will help shape standards that seek to ensure
equitable access to precision prescribing. Register here.
About the American Society of Pharmacovigilance: The
American Society of Pharmacovigilance (ASP) is a 501(c)(3)
nonprofit dedicated to reducing adverse drug events (ADEs), a
leading cause of suffering and mortality in the U.S. As a national
network, ASP is open to healthcare professionals across all
disciplines, united in the mission to address the fourth leading
cause of death in the country. Through collaboration and
innovation, ASP aims to enhance patient safety and healthcare
quality by mitigating the risks associated with ADEs. Our members
are at the forefront of research, education, and advocacy, striving
to create a more responsive and preventative healthcare system. For
more information on how to join or support our mission, visit
https://stopadr.org/.
Contact
Sara Rogers
President
381598@email4pr.com
469-939-8475
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stripe-annual-meeting-and-consensus-workshop-marks-milestone-in-pharmacogenomics-standards-development-302221833.html
SOURCE American Society of Pharmacovigilance